SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-22-133631
Filing Date
2022-04-29
Accepted
2022-04-29 16:08:15
Documents
16
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d488623d10ka.htm   iXBRL 10-K/A 564064
2 EX-31.3 d488623dex313.htm EX-31.3 3937
3 EX-31.4 d488623dex314.htm EX-31.4 3911
  Complete submission text file 0001193125-22-133631.txt   860049

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20211231.xsd EX-101.SCH 4700
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cmpi-20211231_cal.xml EX-101.CAL 687
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmpi-20211231_def.xml EX-101.DEF 19057
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20211231_lab.xml EX-101.LAB 24222
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20211231_pre.xml EX-101.PRE 20337
10 EXTRACTED XBRL INSTANCE DOCUMENT d488623d10ka_htm.xml XML 11569
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39425 | Film No.: 22875339
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences